Renal Cell Carcinoma

Oral tyrosine kinase inhibitor PKI166 limits kidney cancer angiogenesis

Published in Cancer Weekly, December 10th, 2002

by Sonia Nichols, senior medical writer - Researchers in Houston, Texas, say a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor can block angiogenesis in human renal cell carcinoma (HRCC).

The University of Texas M.D. Anderson Cancer Center investigators have studied the effects of PKI166 on HRCCs in vitro and in orthotopic transplantations in nude mice. They have also examined whether or not gemcitabine augments the effects of PKI166.

"In vitro treatment of HRCC cells with PKI166 inhibited EGFR autophosphorylation, which correlated with a decrease in expression of Bcl-xl protein and phosphorylation of signal transducers and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry